At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Jul 29, 2026 at 06:30 ET
MannKind announced positive topline safety and tolerability results from its Phase 1b INFLO-1 study of nintedanib DPI (MNKD-201) in idiopathic pulmonary fibrosis (IPF). The study met its primary endpoint with no serious adverse events, no gastrointestinal side effects, no bronchospasm, and no treatment discontinuations, while cough events were mild and transient. The global Phase 2 INFLO-2 trial is now actively enrolling, supporting continued pipeline development in a large unmet need market.
- Phase 1b INFLO-1 met primary safety/tolerability endpoint in 27 IPF patients across 10 U.S. sites
- No serious adverse events, no drug-related GI side effects, no bronchospasm, no discontinuations or dose reductions
- Cough was predominantly mild/transient with no cough-related discontinuations; ~450 inhalations administered in IPF patients
- Global Phase 2 INFLO-2 actively enrolling ~210 patients across ~85 sites worldwide
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access